 As reported in recent reviews of treatment for IXT, previous studies of occlusion vary regarding the recommended occlusion dose from 3 hours a day to full time, the optimum duration of occlusion treatment from 6 weeks to 42 months, and which eye should be occluded preferreddominant eye or alternate eyes. For the majority of studies, part-time occlusion, rather than full-time occlusion was preferred. In the three occlusion studies conducted prospectively, the recommended dose was either 3 hours a day, 3 to 6 hours a day, or 4 to 6 hours a day, and the duration of occlusion ranged from 3 months to 6 months to up to 42 mean 15 months. Nevertheless, these previous studies of occlusion for the treatment of IXT used a variety of outcome measures at a variety of non-standardized time points; therefore, no definite conclusions can be drawn from the existing literature. 